Cabergoline Therapy and Tumor Growth Rate in Pituitary Microadenomas: A Retrospective Cohort Study
Journal of Clinical Medicine · 08.03.2026 · 15 (5) · 2054
DOI: 10.3390/jcm15052054 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.03.2026. Verfasst von Abdurrahim Tekin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Kanuni Sultan Süleyman Training and Research Hospital, 34303 Istanbul, Türkiye. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare tumor growth rate between patients with pituitary microadenomas who had mild to moderate prolactin elevation and symptoms leading to initiation of cabergoline therapy, and asymptomatic microadenomas without prolactin elevation managed with observation. Materials and Methods: In this retrospective cohort study, 139 patients diagnosed with pituitary microadenoma between 2019 and 2024 and with at least 12 months of clinical and radiological follow-up were included. Patients who received cabergoline therapy due to symptoms were classified as the dopamine agonist-positive [DA(+)] group, while those who did not receive treatment were classified as the dopamine agonist-negative [DA(−)] group. Tumor growth rate was calculated as the annual change (mm/year) in maximum tumor diameter on serial magnetic resonance imaging. Between-group comparisons were performed using the Mann–Whitney U test. A mixed-effects linear model was constructed to evaluate the interaction between time and treatment.
Results
Of the 139 patients included in the study, 42 were in the DA(+) group and 97 were in the DA(−) group. There were no significant differences between the groups in terms of baseline age, follow-up duration, or tumor size (p > 0.05). The mean tumor growth rate was 0.67 ± 0.80 mm/year in the DA(−) group and 0.36 ± 0.38 mm/year in the DA(+) group (p = 0.0208). In the mixed-effects model analysis, the time × treatment interaction was statistically significant (β = −0.021 mm/month; p = 0.009). Patients receiving cabergoline showed a marked reduction in prolactin levels and improvement in symptoms in 78% of cases. Importantly, no tumor shrinkage was observed in either group; the primary observed effect was a reduction in growth velocity rather than true tumor regression. No serious treatment-related adverse effects were observed.
Conclusions
In patients with pituitary microadenomas, cabergoline therapy was associated with a reduced tumor growth rate over time, while no true tumor regression was observed. These findings suggest that cabergoline exposure may influence longitudinal tumor growth dynamics in clinically ambiguous cases encountered in routine practice, without implying definitive tumor subtype classification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Kanuni Sultan Süleyman Training and Research Hospital, 34303 Istanbul, Türkiye.
ORCID-Profile: Abdurrahim Tekin, Evren Sönmez, Akın Öztürk, Nuri Serdar Baş
Zitieren
APA
Tekin, A., Can, E., Sönmez, E., Ayhan, L., Dilbaz, S., Öztürk, A., Edehan, E. F., Çevik, S., & Baş, N. S. (2026). Cabergoline Therapy and Tumor Growth Rate in Pituitary Microadenomas: A Retrospective Cohort Study. Journal of Clinical Medicine, 15(5), 2054. https://doi.org/10.3390/jcm15052054
Vancouver
Tekin A, Can E, Sönmez E, Ayhan L, Dilbaz S, Öztürk A, et al. Cabergoline Therapy and Tumor Growth Rate in Pituitary Microadenomas: A Retrospective Cohort Study. Journal of Clinical Medicine. 2026;15(5):2054. doi:10.3390/jcm15052054
BibTeX
@article{Tekin2026,
author = {Tekin, Abdurrahim and Can, Engin and Sönmez, Evren and Ayhan, Lokman and Dilbaz, Suna and Öztürk, Akın and Edehan, Enis Furkan and Çevik, Serdar and Baş, Nuri Serdar},
title = {Cabergoline Therapy and Tumor Growth Rate in Pituitary Microadenomas: A Retrospective Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {5},
pages = {2054},
doi = {10.3390/jcm15052054}
}
EUVIMED